Abstract:Objective: To develop a novel multi-target small molecule agent for the treatment of hypertension with potential renal protection. Design and method: Part I (preclinical): MT-1207 was tested in the in vitro and in vivo preclinical models to evaluate mechanisms of action, hypertension efficacy, and renal protection. The in vitro activity of MT-1207 was evaluated in enzyme and radioligand binding assays. In vivo Spontaneously Hypertensive Rats (SHR) and two-kidney two-clip (2K2C) rat models were used to evaluate antihypertensive effects and renal protection of MT-1207. Preclinical safety evaluation of MT-1207 was conducted in rats and dogs following ICH guidelines. Part II (clinical): MT-1207 in clinical phases I and II were completed based on the clinical protocols. Phase Ia was a single center, randomized, double-blind, placebo-controlled, dose escalation study to evaluate safety, tolerability, pharmacokinetic of single oral dose of MT-1207 in healthy adult subjects. Phase Ia doses were 5, 10, 20, 40, 60, 90 mg. Similarly, Phase Ib study was conducted in patients with hypertension at 10 and 20 mg (BID) for 10 days. Clinical phase II was a multi-center, randomized, double-blind, placebo- and active-controlled, multiple-dose study to evaluate safety and pharmacodynamics of MT-1207 in patients with hypertension for 8 weeks. Results: Preclinical (part I): MT-1207 showed potent selective inhibitions of Adrenergic 1alpha and Serotonin (5-HT2A) receptors with IC50 < 1 nM. The efficacy of antihypertension of MT-1207 in SHR model was evident with a well-defined dose-response relationship at 2.5, 5, and 10 mpk. In 2K2C rat model, both blood pressure and serum uric acid decreased post-dose at 4-week and 9-week, indicating antihypertensive effects and potential kidney protection, respectively. Clinical (part II): in Phase I, healthy volunteers had good tolerability at 40 mg and below. Rapid blood pressure decreases were observed 1-2 hr post dose in patients with 10 and 20 mg doses. Results from Phase II (10 and 20 mg (BID)) with placebo and active drug (amlodipine) study will be presented including summary of adverse effects (AE) and efficacy data. Conclusions: Clinical data (phases I and II) demonstrated antihypertensive effects of MT-1207 with mild adverse effects.

State space reconstruction : method of delays vs singular spectrum approach

Cardiovascular profile of MPC-1304, a novel dihydropyridine calcium antagonist: comparison with other calcium antagonists

Abstract 5077: Inhibition of Smooth Muscle Myosin, a Novel Anti-Hypertensive Strategy

Role of Losartan and Carvedilol on in Extracellular Signal-Regulated Kinases in Myocardium of Spontaneously Hypertensive Rats

Prevention of myocardial fibrosis by using nitrendipine to the spontaneously hypertensive rats

Pharmacological characterization of MT-1207, a novel multitarget antihypertensive agent

Towards High Accuracy Reflectometry for Extreme-Ultraviolet Lithography

Methyl Palmitate Modulated NMDA-Induced Cerebral Hyperemia in Hypertensive Rats

Neuroprotective Effects of Casein-Derived Peptide Met-Lys-Pro (MKP) in a Hypertensive Model

Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies

PRECLINICAL AND CLINICAL EFFICACY AND SAFETY OF A NOVEL MULTI-TARGET SMALL MOLECULE MT-1207 FOR HYPERTENSION

Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca 2+ -ATPase activity in rat cardiac pressure-overload hypertrophy

New paeonol derivative C302 reduces hypertension in spontaneously hypertensive rats through endothelium-dependent and endothelium-independent vasodilation

The antihypertensive effect of MK on spontaneously hypertensive rats through the AMPK/Akt/eNOS/NO and ERK1/2/Cx43 signaling pathways

[Effects of M-Nifedipine on Activities of Na+,K(+)-ATPase, Ca(2+)-ATPase and Mg(2+)-ATPase in Myocardium and Brain of Elderly Renovascular Hypertensive Rats].

Normal calves produced after transfer of in vitro fertilized embryos cultured with an antiviral compound.

Modulation of left ventricular hypertrophy in spontaneously hypertensive rats by acetylcholinesterase and ACE inhibitors: physiological, biochemical, and proteomic studies

Effects of continuous intermedin infusion on blood pressure and hemodynamic function in spontaneously hypertensive rats

Effects of M-Nifedipine on Dihydropyridine Binding Sites in Cardiac and Cerebral Cortex Cell Membranes from Left Ventricular Hypertrophied Rats.

[Effects of M-Nifedipine on Left Ventricular Diastolic Function and Ca2+ Content of Myocardial and Cerebral Mitochondria and Artery Tissues in Left Ventricular Hypertrophied Rats].

Effects of Intermedin1-53 on Rat Arterial Pressure and Its Mechanism